Amplia MRI Quad CRT-D

Compared to echo-optimized BiV pacing.

** Readmissions following an HF hospitalization.

Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail. July 2015;3(7):565-572.

Martin D, et al. Clinical Outcomes with Adaptive Cardiac Resynchronization Therapy: Long-term Outcomes of the Adaptive CRT Trial. HFSA Late Breakers. September 23, 2013.

Pressure contour plots are scaled relative to each other, header to header, device body to device body. The device body pressure uses an enhanced scaling to demonstrate the pressure differences across the device body; therefore actual pressure is not relative to the header pressure. Note: Analysis for Evera and Device A dual chamber ICDs with DF-4 connectors were used. Analysis for Device B and C used dual chamber ICDs with DF-1 connectors.

Flo. Daniel IS4/DF4 Device Shape Analysis. January 2013. Medtronic data on file.

Ceelen KK. et al. J Biomech. 2008;41:3399-3404.

Sowell LV. et al. J Women's Health. 2006;15:830-835.

Gold MR. et al. J Am Coll Cardiol. 1996;28:1278-1282.

Kolker AR. et al. Ann Plastt Surg. 2007;59:26-30.

Kadish A. et al. Circulation. 2005;111:3327-3335.

Shapiro M. et al. Indian Pacing Electrophyesiol J. 2004;4:213-216.

Eligible devices: Viva™ XT, Viva S, Protecta™ XT, Protecta ICD CRT-D's, Evera MRI™ XT, Evera MRI S, Evera™ XT, Evers S, Protecta XT, Protecta ICDs.

SmartShock Technology algorithims must be programmed "ON" (with parameter settings below) at the time of the inappropriate shock. Medtronic will cover uninsured medical expense, not to exceed $500, per patient shocked event. This offer is valid for the lifetime of the device.

Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. May 2015;12(5):926-936.

Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9, 2005;112(6):841-848.

Abraham WT, Compton S, Haas G, et al. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. November 2009;15(9):813.

Small RS, Whellan DJ, Boyle A, et al. Implantable device diagnostics on the day of discharge from a heart failure hospitalization can predict 30 day readmission risk. J Card Fail. August 2012;18(8 Suppl):S50.

Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.

Whellan DJ, Sarkar S, Koehler J, et al. Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. Am J Cardio. January 1, 2013;111(1):79-84.

Sarkar S, Hettrick DA, Koehler J, et al. Improved algorithm to detect fluid accumulation via intrathoracic impedance monitoring in heart failure patients with implantable devices. J Card Fail. 2011;17(7):569-576.

Medtronic Amplia MRI CRT-D device manuals.